Navigation Links
Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
Date:11/15/2010

to Treat Primary Liver Cancer from the FDA;
  • NCI Consensus published in Journal of Clinical Oncology recommended the Phase III HEAT study as a Priority Clinical Trial for HCC;  
  • Positive FDA guidance relating to 505(b)(2) regulatory submission received for the Company's New Drug Application for ThermoDox® to Treat Primary Liver Cancer;
  • ThermoDox® clinical data presented at the 2010 Breast Cancer Symposium;
  • SBIR grant received to expand technology platform; and
  • Celsion presented at two Healthcare Conferences in New York City.

  • The Company is holding a conference call to provide a business update and discuss the third quarter 2010 results at 3:00 p.m. Eastern Time on November 15, 2010. To participate in the call, interested parties may dial 1-888-218-8172 (Toll free U.S./Canada) or 1-913-312-9313 (Toll/International) and use Conference ID: 4428936 to register ten minutes before the call is scheduled to begin. The call will also be broadcast live on the Internet at http://www.celsion.com.The call will be archived for replay on Monday, November 15, 2010 at 6:00 p.m. Eastern Time and will remain available until Monday, November 22, 2010. The replay can be accessed at 1-877-870-5176 (Toll free U.S./Canada) or 1-858-384-5517 (Toll/International) using Replay Pin: 4428936. An audio replay of the call will also be available on the Company's website, http://www.celsion.com, for 30 days after 5:00 p.m. Eastern Time on November 15, 2010.

    About ThermoDox®ThermoDox® in combination with hyperthermia has the potentia
    '/>"/>

    SOURCE Celsion Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
    2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
    3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
    4. Par Pharmaceutical Reports Second Quarter 2008 Results
    5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    6. Pharmos Corporation Reports 2008 Second Quarter Results
    7. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
    9. BMP Sunstone Reports Second Quarter 2008 Financial Results
    10. ULURU Inc. Reports Second Quarter 2008 Financial Results
    11. Immtech Reports Fiscal First Quarter 2009 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... July 24, 2014  CorMedix Inc. (NYSE MKT: ... commercializing therapeutic products for the prevention and treatment ... of notice on July 18, 2014 from the ... accepted the CorMedix plan to regain compliance with ... result, the NYSE-MKT is continuing the Company,s listing ...
    (Date:7/24/2014)... 2014 Deep Research Report on ... professional and in-depth research report on Potassium Sulphate ... basic information, including its definition, classification, application, and ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis, the influence ...
    (Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
    (Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
    Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
    ... 19 LI-COR Biosciences has released a,new ... gels the Odyssey Infrared,Imaging System. The E-PAGE ... provide a high-throughput SDS-PAGE,method for processing protein samples. ... Blotting System, up to 96 different proteins samples ...
    ... Michigan-based platform company has been built upon the foundation of a ... dynamically build themselves on a wide variety of computational platforms. The ... sagging Michigan economy through the creation of thousands of new jobs ... ...
    ... Md., Nov. 19 PharmAthene, Inc.,(NYSE Alternext US: ... and chemical threats, announced today that,it has signed ... its,biodefense products in Israel. , ... countermeasures to combat the risk of,terrorist attacks with ...
    Cached Biology Technology:Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System 2Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics 2Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics 3Michigan Company Founded upon What Could Be History's Most Important Breakthrough in AI and Robotics 4PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 3PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 4
    (Date:7/25/2014)... 600 scientists from 25 countries and 35 states ... by the Genetics Society of America (GSA) next ... The conference will feature close to 500 presentations ... topics including gene expression and regulation, functional genomics, ... aging, and a variety of diseases. , ...
    (Date:7/25/2014)... New research at the University of Adelaide has opened the ... resistance to powdery mildew. , In Australia, annual barley production ... year. Powdery mildew is one of the most important diseases ... team have discovered the composition of special growths on the ... the fungus into the leaf. , The research, by the ...
    (Date:7/25/2014)... After development of diffusion tensor tractography (DTT), which ... reconstruction and estimation for three motor tracts, such ... the corticoreticular pathway became possible. The corticospinal tract ... for motor function in the human brain. Several ... tract by transtentorial herniation. In addition, some studies ...
    Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2New hope for powdery mildew resistant barley 2
    ... Based on a pilot study in children with sarcoma, ... that immunotherapy could prove beneficial in treating high-risk forms ... novel dendritic vaccine as well as a standard flu ... Their findings, published in the August 1 issue ...
    ... surprisingly simple, inexpensive technique, chemists have found a way ... amounts of electricity, common chemicals and a room-temperature glass ... fuels, many researchers have proposed using solar electricity to ... when the sun goes down. One of the chief ...
    ... NY In the United States, Lyme disease is ... from animals to humans. These animal-borne diseases can make ... and effective intervention are crucial to protecting the public. ... Millbrook, NY recently received $750,000 in grant funding from ...
    Cached Biology News:Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3Water refineries? 2Water refineries? 3EPA funds ground-breaking Lyme disease research 2
    MOUSE ANTI BOVINE CD335:ALEXA 488 Immunogen: Fusion protein consisting of the extracellular region of bovine CD335....
    Template and primers for preparation of internal control spots...
    AedestaTM Animal Organ/Tissue Perfusion Soln....
    Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
    Biology Products: